Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which ablation method best stops atrial fibrillation from returning?

NCT ID NCT07783919

Disease control Sponsor: Marien Hospital Herne Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 25, 2026 · Last updated Aug 26, 2026 · Updated 1 time

Summary

This study compares two catheter ablation techniques for treating atrial fibrillation, a common heart rhythm problem. One method uses a single-shot device, while the other uses a focal dual-energy approach. The trial includes 268 adults with symptomatic atrial fibrillation who are at high risk of recurrence. The goal is to see which technique better prevents abnormal heart rhythms from returning during follow-up.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Catheter ablation using pulsed field energy, comparing single-shot versus focal dual-energy approaches
What this could lead to
If successful, this could identify a more effective ablation technique to reduce atrial fibrillation recurrence and improve long-term heart rhythm control.
What could go wrong
The trial is still in progress, and results may not show a clear advantage for one method. Ablation carries risks like bleeding, infection, or heart rhythm disturbances.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 268 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * First-time pulmonary vein isolation * Symptomatic atrial fibrillation: * Paroxysmal atrial fibrillation (≥ 2 episodes in the last 6 months) and one of the following: CHA2DS2VA score ≥ 2, ≥ 1 cardioversion in the last 6 months or Left atrial (LA) diameter ≥ 45 mm o or persistent atrial fibrillation (≥ 1 episode in the last 6 months) Exclusion Criteria: * Atrial fibrillation due to reversible or non-cardiac causes * Severe mitral or tricuspid valve regurgitation requiring therapy * Previous left atrial endocardial or epicardial ablation * Pregnancy or breastfeeding * Lack of opportunity for reliable study participation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation (AF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation (AF)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Marien Hospital Herne

    Herne, North Rhine-Westphalia, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.